EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers

Val J Lowe iD, Carly T Mester, Emily S Lundt, Jeyeon Lee, Sujala Ghatamaneni, Alicia Algeciras-Schimnich, Michelle R Campbell, Jonathan Graff-Radford, Aivi Nguyen, Hoon-Ki Min, Matthew L Senjem, Mary M Machulda und 12 weitere

Alzheimer's & Dementia · 2024

DOI: 10.1002/alz.14317 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Val J Lowe und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Amyloid beta-Peptides, Biomarkers, Brain. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NIA NIH HHS, Center for Neuroscience Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Understanding the relationship between amyloid beta (Aβ) positron emission tomography (PET) and Aβ cerebrospinal fluid (CSF) biomarkers will define their potential utility in Aβ treatment. Few population‐based or neuropathologic comparisons have been reported. METHODS Participants 50+ years with Aβ PET and Aβ CSF biomarkers (phosphorylated tau [p‐tau]181/Aβ42, n = 505, and Aβ42/40, n = 54) were included from the Mayo Clinic Study on Aging. From these participants, an autopsy subgroup was identified ( n = 47). The relationships of Aβ PET and Aβ CSF biomarkers were assessed cross‐sectionally in all participants and longitudinally in autopsy data. RESULTS Cross‐sectionally, more participants were Aβ PET+ versus Aβ CSF− than Aβ PET− versus Aβ CSF+ with an incremental effect when using Aβ PET regions selected for early Aβ deposition. The sensitivity for the first detection of Thal phase ≥ 1 in longitudinal data was higher for Aβ PET (89%) than p‐tau181/Aβ42 (64%). DISCUSSION Aβ PET can detect earlier cortical Aβ deposition than Aβ CSF biomarkers. Aβ PET+ versus Aβ CSF− findings are several‐fold greater using regional Aβ PET analyses and in peri‐threshold‐standardized uptake value ratio participants. Highlights Amyloid beta (Aβ) positron emission tomography (PET) has greater sensitivity for Aβ deposition than Aβ cerebrospinal fluid (CSF) in early Aβ development. A population‐based sample of participants ( n = 505) with PET and CSF tests was used. Cortical regions showing early Aβ on Aβ PET were also used in these analyses. Neuropathology was used to validate detection of Aβ by Aβ PET and Aβ CSF biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyAmyloid beta-PeptidesBiomarkersBraintau ProteinsAlzheimer DiseaseHumansFemaleMaleAgedMiddle AgedCross-Sectional StudiesPeptide FragmentsLongitudinal StudiesAged, 80 and overAutopsy

Stichwörter der Autor:innen

Alzheimer's diseasePittsburgh compound Bamyloid betaautopsycerebrospinal fluidneuropathologypositron emission tomography

Substanzen

Amyloid beta-PeptidesBiomarkerstau ProteinsPeptide Fragmentsamyloid beta-protein (1-42)

Autor:innen und Institutionen

  • Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Departments of Radiology and Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Biomedical Engineering, College of Medicine, Hanyang University, Seoul, Republic of Korea.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Information Technology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Val J Lowe

Förderung

  • NIH HHS
  • NIA NIH HHS
  • Center for Neuroscience Research
  • NINDS NIH HHS
  • The Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic
  • Elsie and Marvin Dekelboum Family Foundation
  • The Schuler Foundation
  • GHR Foundation

Zitieren

APA

Lowe, V. J., Mester, C. T., Lundt, E. S., Lee, J., Ghatamaneni, S., Algeciras-Schimnich, A., Campbell, M. R., Graff-Radford, J., Nguyen, A., Min, H. K., Senjem, M. L., Machulda, M. M., Schwarz, C. G., Dickson, D. W., Murray, M. E., Kandimalla, K. K., Kantarci, K., Boeve, B., Vemuri, P., …, & Mielke, M. M. (2024). Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14317

Vancouver

Lowe VJ, Mester CT, Lundt ES, Lee J, Ghatamaneni S, Algeciras-Schimnich A, et al. Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers. Alzheimer's & Dementia. 2024. doi:10.1002/alz.14317

BibTeX
@article{Lowe2024,
  author = {Lowe, Val J and Mester, Carly T and Lundt, Emily S and Lee, Jeyeon and Ghatamaneni, Sujala and Algeciras-Schimnich, Alicia and Campbell, Michelle R and Graff-Radford, Jonathan and Nguyen, Aivi and Min, Hoon-Ki and Senjem, Matthew L and Machulda, Mary M and Schwarz, Christopher G and Dickson, Dennis W and Murray, Melissa E and Kandimalla, Karunya K and Kantarci, Kejal and Boeve, Bradley and Vemuri, Prashanthi and Jones, David T and Knopman, David and Jack, Clifford R and Petersen, Ronald C and Mielke, Michelle M},
  title = {Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  doi = {10.1002/alz.14317}
}
Kostenlos starten →